Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

brequinar sodium

Known as: Sodium 6-Fluoro-2-(2'-fluoro-4-biphenylyl)-3-methyl-4-quinolinecarboxylate 
The sodium salt form of Brequinar. Brequinar inhibits the enzyme dihydroorotate dehydrogenase, thereby blocking de novo pyrimidine biosynthesis. This… Expand
National Institutes of Health

Related topics

Related topics

2 relations

Narrower (1)

DuP 785
brequinar

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2000
2000
Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid.
Mitochondrially-bound dihydroorotate dehydrogenase (EC 1.3.99.11) catalyzes the fourth sequential step in the de novo synthesis… Expand
Is this relevant?
Highly Cited
1996
Highly Cited
1996
The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase.
The active metabolite of leflunomide. A771726, is a novel immunosuppressive compound that has been shown to be a powerful… Expand
Is this relevant?
Review
1993
Review
1993
The development of Brequinar as an immunosuppressive drug for transplantation.
The preclinical and clinical characterization of Brequinar sodium has demonstrated the potential for the use of this drug as a… Expand
Is this relevant?
1993
1993
Multicenter phase II study of brequinar sodium in patients with advanced breast cancer.
In this study, 34 patients with advanced breast cancer were treated with brequinar sodium: 75% of the patients were… Expand
Is this relevant?
1992
1992
Inhibition of dihydroorotate dehydrogenase activity by brequinar sodium.
The novel anticancer drug candidate brequinar sodium (DuP 785, NSC 368390, 6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 5
Is this relevant?
1992
1992
The effect of a new immunosuppressive drug, brequinar sodium, on heart, liver, and kidney allograft rejection in the rat.
Brequinar sodium (BQR) prevents cell proliferation by virtue of its inhibition of de novo pyrimidine biosynthesis. BQR is capable… Expand
Is this relevant?
1992
1992
Therapy of chronic relapsing experimental allergic encephalomyelitis and the role of the blood-brain barrier: elucidation by the action of Brequinar sodium
The immunosuppressive effect of the novel 4-quinoline carboxylic acid derivative Brequinar sodium on the chronic relapsing… Expand
Is this relevant?
1990
1990
In vivo inhibition of the pyrimidine de novo enzyme dihydroorotic acid dehydrogenase by brequinar sodium (DUP-785; NSC 368390) in mice and patients.
Little is known about the in vivo effects of inhibition of the mitochondrial pyrimidine de novo synthesis enzyme dihydroorotic… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?
1990
1990
Phase I and pharmacokinetic study of brequinar sodium (NSC 368390).
Brequinar sodium is a quinoline carboxylic acid derivative that has shown antitumor activity in a number of in vivo murine and… Expand
Is this relevant?
1989
1989
Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).
Brequinar sodium is a 4-quinolinecarboxylic acid analogue that inhibits dihydroorotate dehydrogenase and subsequent de novo… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE